中文
русский
Home
|
Set As Homepage
News
About us
Over View
Enterprise Culture
History
Organization
Health & Wellness
Women Health & Wellness
Popular contraceptive methods
Products
Dietary Supplement
Women Healthcare Products
Contraceptives
Medical Abortion
Hormone Replacement Therapy
Endometriosis
Ophthalmology Medicines
APIs and Intermediates
APIs
Intermediates
Anesthetic
Biological Agents
Respiratory medicine
R & D
Product R&D
Authentication
Foreign Affairs
Introduction
Foreign Cooperation
Business Scope
Contact Us
Our News
Joining in Capacity Building Workshop with Chinese RHC Vendors in Wuha...
2021/6/1
Pharmacovigilance
2019/12/25
First co-pack of mifepristone oral tablet and misoprostol for vaginal ...
2019/11/26
Zizhu’s misoprostol receives WHO prequalification
2016/11/24
Mifepristone200mg Tablets approved by WHO Prequalification
2016/8/16
API China & PHARMPACK & SINOPHEX 2016
2016/4/18
TESTOSTERONE has received CEP
2016/1/7
APIs of QZP approved by COFEPRIS of Mexico
2015/7/6
CRZP has received WHO prequalification
2014/11/6
APIs of QZP approved by FDA
2014/11/2
APIs of QZP approved by WHO-PQ
2013/9/3
First reproductive health API receives WHO prequalification
2013/7/16
BZP has renamed as CRZP
2013/7/16
Zizhu Passed WHO and FDA GMP Inspections
2012/12/6
2011 China Health Annual Billboard
2012/1/30
Qinhuangdao Zizhu rewarded the API GMP
2012/1/12
API GMP for Testosterone
2012/1/12
Zizhu has been rewarded the OHSAS18001 certificate by TÜVAnlagent...
2011/8/16
Zizhu passed the reevaluation of the ISO9001:2000 quality system on No...
2011/8/16
Zizhu pharmaceutical obtained ISO10012 certificate
2011/8/16
Levonorgestrel Tablets(0.75mg) and Mifepristone were awarded the “ Fa...
2011/8/16
Zizhu successfully passed the ISO14001 environmental system reevaluati...
2011/8/16
Industry News
Stumbling Blocks to Contraceptive Services
2012/9/21
09.26.12 World Contraception Day
2012/9/21
Contraceptives: A Global Strategic Business Report
2011/8/22
Contraceptive Market To 2016
2011/8/22
Contraceptive prevalence
2011/8/22
Hormone Replacement Therapy (HRT): A Global Strategic Business Report
2011/8/22
Top News
Joining in Capacity Build...
Joining in Capacity Building Workshop with Chinese RHC Vendors in Wuhan
Pharmacovigilance
Adverse Drug Reaction Information Registration Form
Contact:
Tel: +86-10-65483355 Fax: +86-10-62245401
E-Mail:
zizhu@zizhu-pharm.com
China Resources
Zizhu
Pharmaceutical Co.,Ltd
Home
|
News
|
About us
|
Health & Wellness
|
Products
|
R & D
|
Foreign Affairs
京 ICP备10215952号-2
Copyright© 2011-2021